|

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

RECRUITINGSponsored by Astellas Pharma Inc
Actively Recruiting
SponsorAstellas Pharma Inc
Started2019-09-02
Est. completion2026-05-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03971253

Summary

The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.

Exclusion Criteria:

* Not applicable.

Conditions2

ArthritisRheumatoid Arthritis (RA

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.